Objective To investigate the renal function improvement effects and influencing factors of CKD25 patients combined with hyperuricemia after hypouric acid therapy to provide more reference for clinical treatment with followup.Methods Clinical data of 264 patients with CKD for 25 stage combined with hyperuricemia were retrospectively chosen in the period from March 2014 to June 2018 in Fourth People's Hospital of Shenyang and divided according to eGFR levels at admission into control group (122 patients) with CKD23a stage and observation group (142 patients) with CKD3b5 stage. The levels of serum uric acid and related indicators of renal function before and after treatment of both groups were compared and the difference of eGFR levels between serum uric acid uptostandard group and nonuptostandard group and the relationship between eGFR values of serum uric acid and deGFR and SUA were analyzed. Results The levels of serum uric acid, Scr, BUN and eGFR in the first, the third and sixth months after receiving hypouric acid therapy were significantly higher than that at admission（P＜0.05）. There was no significant difference in the levels of SUA after treatment between the two groups（P＞0.05）. The levels of eGFR and deGFR of control group were significantly better than that of observation group and before treatment（P＜0.05）. Multiple linear regression analysis showed that the levels of eGFR was the independent factor affecting the deGFR level of patients at admission（b=0178，P=003）. The levels of serum uric acid, eGFR and deGFR after treatment of patients with serum uric acid uptostandard were significantly higher than serum uric acid non uptostandard（P＜0.05）. Conclusion Hypouric acid therapy in the treatment of patients with CKD25 stage combined with hyperuricemia can effectively reduce the levels of proteinuria and improve renal function. The levels of deGFR after treatment should be closely related to the levels of eGFR at admission.